Author

P. Pertel

Observed names: Patricia Pertel, Pertel, Patricia

Institutions: Novartis (Switzerland), Seoul National University

Observed institutions: Novartis (Switzerland), Seoul National University

OpenAlex ID: A5023212323

Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study

2024 · Xenofon Baraliakos, Mikkel Østergaard, et al. · Arthritis & Rheumatology · 38

Pos1115 Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status

2023 · X. Baraliakos, D. Van der Heijde, et al. · 3

AB0759 Efficacy of secukinumab in patients with non-radiographic axial spondyloarthritis: analysis by symptom duration and age

2022 · A. Deodhar, D. Poddubnyy, et al. · Annals of the Rheumatic Diseases

POS0937 MEASURE 2: SECUKINUMAB PROVIDES RAPID AND SUSTAINED RELIEF FROM KEY CLINICAL SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN TNFi-NAÏVE PATIENTS THROUGH 5 YEARS

2022 · K. Pavelka, A. Kivitz, et al. · Annals of the Rheumatic Diseases

Works count: 5

Citation count: 41

H-index: 2

I10-index: 1